BALDERTON-CAPITAL
12.8.2024 08:01:30 CEST | Business Wire | Press release
Balderton Capital, one of Europe’s leading technology venture capital firms, today announced its $615 million Early Stage Fund IX and $685 million Growth Fund II, to back Europe’s most ambitious entrepreneurs from seed stage through IPO.
“At Balderton, we believe the best way to change the world is to build a business - and that many of these world-changing businesses will be built in Europe,” said Bernard Liautaud, Managing Partner at Balderton. “As a firm, our mission is simple: to be the partner of choice to the founders starting and growing those European technology companies. These new funds put us in a position to do just that.”
There was strong investor demand for Early Stage Fund IX and Growth Fund II, which marked the first time Balderton raised its early and growth funds simultaneously. The increasingly global mix of LPs in the firm’s funds have been attracted to Balderton’s European focus and track record of success during its 25 year history. This includes one of the largest and most prominent public state pensions in the United States, building out a selective European VC portfolio, and British Patient Capital, the UK's largest domestic investor in venture and venture growth opportunities.
There is now a long and diverse history of Europe as a key hub for global tech, with proven winners across sectors and countries. In just the last two years, Europe has established itself as a leader in AI, with London and Paris being the key innovation centres. The reasons for this are not surprising or new: world class institutions and engineers, a growing culture of entrepreneurialism, a developed funding ecosystem and, increasingly, third and fourth generation founders.
The growth of the European technology ecosystem has created strong returns for investors as well. European VC funds outperformed North American funds over both a 10 and 15 year period, according to data from Invest Europe and Cambridge Associates.
Since its founding in 2000, Balderton has invested in more than 275 technology companies from across Europe. The current portfolio includes global category leaders like Revolut, Dream Games, GoCardless, Contentful, Aircall, Wayve, Writer and PhotoRoom. Many previous portfolio companies have successfully exited, such as Darktrace, Depop, MySQL, Peakon, Recorded Future, Talend and THG. Balderton’s investment history spans technology sectors including AI, fintech, B2B SaaS, digital health, mobility, gaming and marketplaces.
Beyond the hands-on support from its investment team, who have invaluable operational and entrepreneurial experience, Balderton offers a range of services to its founders and portfolio companies, including:
- The Balderton Platform team, comprising experts in legal, finance, talent and people, marketing and sustainability
- Executives in Residence - industry veterans with decades of experience as startup builders and operators, with expertise in areas including sales, engineering, product and legal
- The Balderton Community of more than 700 leading European technology executives from across the portfolio, who come together for peer support, networking and events, and form one of the strongest startup networks in Europe
In addition, Balderton takes unprecedented steps to support founders through its industry-leading Balderton Founder Wellbeing and Performance platform. This covers executive coaching, peer to peer support in CEO Forums, a health and fitness program and access to a digital platform for parent founders.
With Balderton’s 65 team members across Europe, $1.3bn in new funds, and a strong portfolio of more than 125 companies, the firm is excited to continue its work of partnering with Europe’s top entrepreneurs as they build world-changing companies.
About Balderton Capital
Balderton Capital is a multistage venture firm with more than two decades of experience supporting Europe’s best founders from Seed to IPO. We have both early and growth funds and invest across the technology sector, with a proven track record backing AI, fintech, B2B SaaS, digital health, mobility, gaming and marketplace companies. Previous investments include Darktrace (LON: DARK), Depop, Flywire (NASDAQ: FLYW), Kobalt, MySQL, Nutmeg, Peakon, Recorded Future, Talend (NASDAQ: TLND) and THG (LON: THG). Balderton’s current portfolio includes: Aircall, Beauty Pie, Contentful, Dream Games, GoCardless, Lendable, Matillion, Merama, Photoroom, Revolut, Tibber, Wayve, Writer and ZOE.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808083911/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom